0.1399
price up icon5.27%   0.007
after-market After Hours: .14 0.0001 +0.07%
loading
Spruce Biosciences Inc stock is traded at $0.1399, with a volume of 2.32M. It is up +5.27% in the last 24 hours and down -57.59% over the past month. Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
See More
Previous Close:
$0.1329
Open:
$0.1346
24h Volume:
2.32M
Relative Volume:
2.37
Market Cap:
$5.01M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-0.1488
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
+17.86%
1M Performance:
-57.59%
6M Performance:
-76.09%
1Y Performance:
-80.07%
1-Day Range:
Value
$0.128
$0.14
1-Week Range:
Value
$0.1151
$0.14
52-Week Range:
Value
$0.11
$0.87

Spruce Biosciences Inc Stock (SPRB) Company Profile

Name
Name
Spruce Biosciences Inc
Name
Phone
(415) 655-4168
Name
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Name
Employee
21
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
SPRB's Discussions on Twitter

Compare SPRB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SPRB
Spruce Biosciences Inc
0.1399 5.01M 7.10M -39.43M -46.50M -0.94
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-11-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Dec-11-24 Downgrade Oppenheimer Outperform → Perform
Mar-14-24 Downgrade Guggenheim Buy → Neutral
Mar-14-24 Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-14-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-14-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-21-24 Initiated Guggenheim Buy
Dec-17-21 Initiated Oppenheimer Outperform
Dec-10-21 Initiated The Benchmark Company Speculative Buy
Nov-16-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-19-21 Initiated H.C. Wainwright Buy
Apr-26-21 Resumed Credit Suisse Outperform
Nov-03-20 Initiated Cowen Outperform
Nov-03-20 Initiated Credit Suisse Outperform
Nov-03-20 Initiated RBC Capital Mkts Outperform
Nov-03-20 Initiated SVB Leerink Outperform
View All

Spruce Biosciences Inc Stock (SPRB) Latest News

pulisher
Apr 24, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences By Investing.com - Investing.com Nigeria

Apr 24, 2025
pulisher
Apr 23, 2025

Citizens JMP maintains Market Perform on Spruce Biosciences - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

The Potential Rise in the Price of Spruce Biosciences Inc (SPRB) following insiders activity - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

TD Cowen reiterates NextDecade Corporation (NEXT) stock to a Buy - knoxdaily.com

Apr 22, 2025
pulisher
Apr 19, 2025

Q1 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives $2.17 Consensus Target Price from Analysts - Defense World

Apr 19, 2025
pulisher
Apr 17, 2025

Spruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call Transcript - Insider Monkey

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Biosciences Inc (NASDAQ: SPRB) Slashes -6.82%: What Could Be On The Way Going Forward? - stocksregister.com

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Bio sows the seeds of its new future - Pharmaphorum

Apr 17, 2025
pulisher
Apr 17, 2025

Spruce Pivots After Pipeline Failure With BioMarin Tralesinidase Deal - insights.citeline.com

Apr 17, 2025
pulisher
Apr 16, 2025

Spruce Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 16, 2025
pulisher
Apr 16, 2025

RBC Cuts Price Target on Spruce Biosciences to $0.50 From $1.50, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025
pulisher
Apr 16, 2025

Spruce Biosciences Announces New Corporate Strategy and Acquisit - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

With BioMarin deal, Spruce Biosciences hits reset on rare-disease drugSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences Acquires Tralesinidase Alfa From BioMarin - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

SPRB stock touches 52-week low at $0.18 amid market challenges - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences (SPRB) Acquires New Therapy for Rare Disease Treatment | SPRB Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences plans BLA for rare disease therapy - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

SPRUCE BIOSCIENCES, INC. SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Spruce Biosciences Announces New Corporate Strategy And Acquisition Of Tralesinidase Alfa - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Major Rare Disease Breakthrough: Spruce Bio Secures Promising Treatment for Fatal Childhood Disease - Stock Titan

Apr 15, 2025
pulisher
Apr 11, 2025

Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace

Apr 11, 2025
pulisher
Apr 08, 2025

Levi & Korsinsky Reminds Shareholders of an Investigation into Spruce Biosciences, Inc. (SPRB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

SPRB stock touches 52-week low at $0.26 amid market challenges - Investing.com India

Apr 07, 2025
pulisher
Apr 07, 2025

Congenital Adrenal Hyperplasia Treatment Market: Key Trends, - openPR.com

Apr 07, 2025
pulisher
Apr 01, 2025

Spruce Biosciences reports delayed annual filing By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Spruce Biosciences reports delayed annual filing - Investing.com

Apr 01, 2025
pulisher
Mar 31, 2025

Spruce Biosciences Delays Annual Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 31, 2025
pulisher
Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 - Investing.com

Mar 25, 2025
pulisher
Mar 25, 2025

In-Depth Analysis Of The Global Congenital Adrenal Hyperplasia Market: Key Drivers, Trends, Growth Opportun... - WhaTech

Mar 25, 2025
pulisher
Mar 25, 2025

Spruce Biosciences stock hits 52-week low at $0.32 By Investing.com - Investing.com Canada

Mar 25, 2025
pulisher
Mar 22, 2025

SPRUCE BIOSCIENCES INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com

Mar 22, 2025
pulisher
Mar 20, 2025

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance

Mar 20, 2025
pulisher
Mar 14, 2025

Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) PT at $2.38 - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

SPRB Stock Touches 52-Week Low at $0.34 Amid Steep Decline - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025

Spruce Biosciences Inc Stock (SPRB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):